Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Maternal streptococcal B vaccine costeffective in sub-Sahara

Maternal streptococcal B vaccine costeffective in sub-Sahara PharmacoEconomics & Outcomes News 792, p17 - 2 Dec 2017 Maternal streptococcal B vaccine cost effective in sub-Sahara Streptococcal B (GBS) vaccination in pregnant women appears to be cost effective for the prevention of neonatal sepsis and meningitis in low-income countries in sub-Saharan Africa, according to findings of a study published in Vaccine. A decision tree and Markov model populated with data from published literature was used to evaluate the cost effectiveness of maternal GBS immunisation for the prevention of early-onset and late-onset GBS cases and deaths in infants in Ghana, Guinea-Basseau, Nigeria and Uganda, compared with no GBS immunisation. Cost effectiveness was assessed based on two benchmarks: 0.5 GDP and GDP per capita per disability-adjusted life-year (DALY) averted. The ** assumed cost of the vaccine was $7 per dose, and the assumed vaccine efficacy rate against serotypes was 70%. It was assumed that vaccine coverage was equivalent to the proportion of pregnant women who underwent four or more antenatal visits (ANC4). Maternal GBS vaccination was estimated to prevent 30%–34% of GBS cases and deaths in Uganda and Nigeria (ANC4 48% and 51%, respectively), 42-43% of cases and deaths in Guinea-Bissau (ANC4 65%), and 55%–57% of cases and deaths http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Maternal streptococcal B vaccine costeffective in sub-Sahara

PharmacoEconomics & Outcomes News , Volume 792 (1) – Dec 2, 2017
Download PDF
1 page

Maternal streptococcal B vaccine costeffective in sub-Sahara

Abstract

PharmacoEconomics & Outcomes News 792, p17 - 2 Dec 2017 Maternal streptococcal B vaccine cost effective in sub-Sahara Streptococcal B (GBS) vaccination in pregnant women appears to be cost effective for the prevention of neonatal sepsis and meningitis in low-income countries in sub-Saharan Africa, according to findings of a study published in Vaccine. A decision tree and Markov model populated with data from published literature was used to evaluate the cost effectiveness of maternal GBS...
Loading next page...
 
/lp/springer_journal/maternal-streptococcal-b-vaccine-costeffective-in-sub-sahara-vDToPf5XRc

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
DOI
10.1007/s40274-017-4540-4
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 792, p17 - 2 Dec 2017 Maternal streptococcal B vaccine cost effective in sub-Sahara Streptococcal B (GBS) vaccination in pregnant women appears to be cost effective for the prevention of neonatal sepsis and meningitis in low-income countries in sub-Saharan Africa, according to findings of a study published in Vaccine. A decision tree and Markov model populated with data from published literature was used to evaluate the cost effectiveness of maternal GBS immunisation for the prevention of early-onset and late-onset GBS cases and deaths in infants in Ghana, Guinea-Basseau, Nigeria and Uganda, compared with no GBS immunisation. Cost effectiveness was assessed based on two benchmarks: 0.5 GDP and GDP per capita per disability-adjusted life-year (DALY) averted. The ** assumed cost of the vaccine was $7 per dose, and the assumed vaccine efficacy rate against serotypes was 70%. It was assumed that vaccine coverage was equivalent to the proportion of pregnant women who underwent four or more antenatal visits (ANC4). Maternal GBS vaccination was estimated to prevent 30%–34% of GBS cases and deaths in Uganda and Nigeria (ANC4 48% and 51%, respectively), 42-43% of cases and deaths in Guinea-Bissau (ANC4 65%), and 55%–57% of cases and deaths

Journal

PharmacoEconomics & Outcomes News – Springer Journals

Published: Dec 2, 2017

There are no references for this article.